已出刊文章

【綜合評述】Finerenone:從心腎保護走向HFmrEF / HFpEF 治療
Finerenone: Moving Beyond Cardiorenal Protection Toward HFmrEF/HFpEF Therapy
finerenone、射出分率輕度降低的心衰竭、射出分率保留的心衰竭、finerenone, HFmrEF, HFpEF
謝宛錚Wan-Cheng Hsieh1 、楊璦瑜Ai-Yu Yang1,*
1高雄醫學大學附設中和紀念醫院 藥學部

摘要
射出分率輕度降低(heart failure with mildly reduced ejection fraction, HFmrEF) 與射出分率保留(heart failure with preserved ejection fraction, HFpEF) 的心衰竭占所有心衰竭病人的半數以上,傳統神經內分泌拮抗藥物在此族群中缺乏明確改善預後的證據。
Finerenone 為新型非類固醇選擇性礦物皮質類固醇受體拮抗劑(mineralocorticoid receptor antagonist, MRA),相較於傳統類固醇MRA,如spironolactone 與eplerenone,具有較高的MR (mineralocorticoid receptor) 親和力與受體選擇性,可避免男性女乳症等內分泌副作用。其於心腎組織間呈均衡分布,半衰期短,發生高血鉀時可透過停藥迅速處理。
FIDELITY 整合分析顯示finerenone 可降低心血管複合終點風險14% (HR [hazard ratio]: 0.86, 95% CI [confidence interval]: 0.78–0.95)、心衰住院風險22% (HR: 0.78, 95% CI: 0.66–0.92)。FINEARTS-HF 試驗收納左心室射出分率 ≥40% 的心衰病人,結果顯示finerenone 可顯著降低主要複合終點(心衰惡化事件與心血管死亡)達16% (RR [risk ratio]: 0.84, 95% CI: 0.74–0.95, p = 0.007)、心衰住院風險降低18% (RR: 0.82, 95% CI: 0.71–0.95),但心血管死亡與全死因死亡未達顯著差異。
Finerenone 為HFmrEF / HFpEF 治療開啟新篇章,臨床上依據腎功能與電解質調整藥物劑量,以達療效與安全性並重。
 
ABSTRACT
Heart failure with mildly reduced ejection fraction (HFmrEF) and heart failure with preserved ejection fraction (HFpEF) account for more than half of all heart failure cases. Traditional neurohormonal antagonists have shown limited evidence in improving prognosis in this population.
Finerenone is a novel nonsteroidal selective mineralocorticoid receptor antagonist (MRA). Compared with steroidal MRAs such as spironolactone and eplerenone, finerenone demonstrates higher MR (mineralocorticoid receptor) affinity and receptor selectivity, thereby avoiding endocrine-related adverse effects such as gynecomastia. It exhibits balanced distribution between cardiac and renal tissues and has a short halflife, allowing rapid management of hyperkalemia through drug discontinuation.
The FIDELITY pooled analysis demonstrated that finerenone reduced the risk of composite cardiovascular endpoints by 14% (HR [hazard ratio] 0.86, 95% CI [confidence interval] 0.78–0.95) and heart failure hospitalization by 22% (HR: 0.78, 95% CI: 0.66– 0.92). The FINEARTS-HF trial enrolled patients with heart failure and left ventricular ejection fraction ≥40%, showing that finerenone significantly reduced the primary composite endpoint (worsening heart failure events and cardiovascular death) by 16% (RR [risk ratio] 0.84, 95% CI 0.74–0.95, p = 0.007) and heart failure hospitalization by 18% (RR 0.82, 95% CI 0.71–0.95). However, cardiovascular death and all-cause mortality did not reach statistical significance.
Finerenone represents a new chapter in the treatment of HFmrEF/HFpEF. Individualized dosing based on renal function and electrolyte status is essential to optimize both efficacy and safety.
 

Submitted for publication: 2026.01.05; Accepted for publication: 2026.01.16

操作進行中,請稍候~~~~
×
加载中...

系統通知

不再顯示此通知
×